Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Maira, Sauveur-Michel, Stauffer, Frédéric, Brueggen, Josef, Furet, Pascal, Schnell, Christian, Fritsch, Christine, Brachmann, Saskia, Chène, Patrick, De Pover, Alain, Schoemaker, Kevin, Fabbro, Doriano, Gabriel, Daniela, Simonen, Marjo, Murphy, Leon, Finan, Peter, Sellers, William, García-Echeverría, Carlos · 2008 · Molecular Cancer Therapeutics

Published version of a preprint

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention. NVP-BEZ235 is an imidazo[4,5-c]quinoline derivative that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. In cellular settings using human tumor cell lines, this molecule is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest. The cellular activity of NVP-BEZ235 translates well in in vivo models of human cancer. Thus, the compound was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies. Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues showed a time-dependent correlation between compound concentration and PI3K/Akt pathway inhibition. Collectively, the preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties. NVP-BEZ235 is currently in phase I clinical trials. [Mol Cancer Ther 2008;7(7):1–13 [Mol Cancer Ther 2008;7(7):1851–13]

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-08-0017

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 1,134

Metadata

Authors
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., Fabbro, D., Gabriel, D., Simonen, M., Murphy, L., Finan, P., Sellers, W., & García-Echeverría, C.
Affiliations
  • 1Oncology Disease Area and
  • 3Novartis Vaccines and Diagnostics, Inc., Emeryville, California; and
  • Novartis (Switzerland) (CH)
  • 4Developmental and Molecular Pathways and
  • 5Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
Venue
Molecular Cancer Therapeutics
Published
2008-07-01
Volume
7
Issue
7
Pages
1851-1863
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2158305336
Cited by
1,134
References
50
Citations by year
2026: 12 · 2025: 25 · 2024: 19 · 2023: 25 · 2022: 24 · 2021: 39 · 2020: 55 · 2019: 51 · 2018: 54 · 2017: 64 · 2016: 68 · 2015: 100 · 2014: 99 · 2013: 106 · 2012: 105
FWCI
42.46
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
NVP-BEZ235, PI3K/mTOR inhibitors, dual PI3K/mTOR inhibition, PI3K/Akt signaling, mTOR kinase, G1 cell cycle arrest, oral anticancer drugs, combination chemotherapy, pharmacokinetics, pharmacodynamics, tumor models, anticancer activity
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Adenosine Triphosphate, Administration, Oral, Animals, Antineoplastic Agents, Cell Cycle, Dose-Response Relationship, Drug, Glioblastoma, Humans, Imidazoles, Mice, Nude, Protein Kinases, Quinolines, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Proto-Oncogene Proteins c-akt, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. https://app.cochat.ai/papers/10.1158/1535-7163.mct-08-0017
The paper
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., Fabbro, D., Gabriel, D., Simonen, M., Murphy, L., Finan, P., Sellers, W., & García-Echeverría, C. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-08-0017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.